Starling Oncology (STLNW) EBITDA Margin (2021 - 2026)
Starling Oncology's (STLNW) quarterly EBITDA Margin came in at 2.17% in Q2 2026, up 633.0% on a YoY basis from 0.3% in Q2 2025, and up 43.08% quarter-over-quarter from 3.81% in Q1 2026.
Powered by 
Analysis
Starling Oncology (STLNW) EBITDA Margin (2021 - 2026) Analysis & Trends
Starling Oncology (STLNW) has reported EBITDA Margin for 6 consecutive years, with 2.17% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin rose 633.0% year-over-year to 2.17%; the trailing twelve-month figure through Jun 2026 stood at 3.77% (up 639.0% YoY), and the FY2025 full-year result was 6.39%, up 808.0% from the prior year.
- EBITDA Margin advanced to 2.17% in Q2 2026 per STLNW's latest filing, from 3.81% in the prior quarter.
- Across five years, EBITDA Margin topped out at 2.17% in Q2 2026 and bottomed at 42.43% in Q1 2023.
- Historically, EBITDA Margin has averaged 17.26% across 5 years, with a median of 15.85% in 2024.
- The widest YoY moves for EBITDA Margin: up 4310 bps in 2022, down 2965 bps in 2022.
- Over 5 years, EBITDA Margin stood at 34.47% in 2022, then soared by 51 bps to 16.88% in 2023, then jumped by 35 bps to 10.97% in 2024, then surged by 62 bps to 4.22% in 2025, then soared by 49 bps to 2.17% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 2.17%, 3.81%, and 4.22% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Davita | 11.89 Bn | 11.20 Bn | 1.16 Bn | 16.29% |
| 2 | RadNet | 5.51 Bn | 4.78 Bn | 88.08 Mn | 6.34% |
| 3 | Fresenius Medical Care AG | 4.79 Bn | 4.09 Bn | 1.52 Bn | 9.58% |
| 4 | Concentra Group Holdings Parent | 4.28 Bn | 4.12 Bn | 192.10 Mn | 18.99% |
| 5 | Privia Health | 2.57 Bn | 2.16 Bn | - | 1.88% |
| 6 | Pediatrix Medical | 2.14 Bn | 1.74 Bn | - | 11.67% |
| 7 | Progyny | 2.11 Bn | 1.87 Bn | 89.30 Mn | 11.41% |
| 8 | Surgery Partners | 1.85 Bn | 1.63 Bn | 622.10 Mn | 12.03% |
| 9 | U S Physical Therapy | 1.18 Bn | 1.15 Bn | 41.94 Mn | 10.25% |
| 10 | Starling Oncology | 4.13 Mn | -36.96 Mn | 27.17 Mn | -2.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.17% |
| Mar 31, 2026 | -3.81% |
| Dec 31, 2025 | -4.22% |
| Sep 30, 2025 | -5.16% |
| Jun 30, 2025 | -8.50% |
| Mar 31, 2025 | -8.52% |
| Dec 31, 2024 | -10.97% |
| Sep 30, 2024 | -13.07% |
| Jun 30, 2024 | -15.84% |
| Mar 31, 2024 | -18.23% |
| Dec 31, 2023 | -16.88% |
| Sep 30, 2023 | -15.86% |
| Jun 30, 2023 | -17.87% |
| Mar 31, 2023 | -42.43% |
| Dec 31, 2022 | -34.47% |
| Sep 30, 2022 | -30.32% |
| Jun 30, 2022 | -29.46% |
| Mar 31, 2022 | -32.92% |
| Dec 31, 2021 | -77.56% |
| Sep 30, 2021 | -3.70% |